Variant cheat sheet · metastatic colorectal cancer

BRAF V600E in metastatic colorectal cancer

Free clinical reference. Educational use only — not a substitute for professional medical advice.

TL;DR

BRAF V600E in mCRC is AMP/ASCO/CAP Tier I-A for the combination of encorafenib + cetuximab (BEACON CRC, post-1L). BRAF inhibitor monotherapy fails in CRC due to feedback EGFR reactivation; the EGFR antibody is essential. MSI status must be co-tested: MSI-H BRAF V600E may favor checkpoint inhibitor therapy first.

Biology

BRAF V600E is a constitutively active serine/threonine kinase in the MAPK pathway. In colorectal cancer, unlike melanoma, BRAF inhibition alone causes rapid feedback activation of EGFR, which restores MAPK signaling and drives resistance. This is why monotherapy BRAFi failed in CRC and combination with anti-EGFR (cetuximab) is required.

Epidemiology

BRAF V600E occurs in ~8-10% of mCRC, more common in right-sided tumors, older patients, and women. It is a strong negative prognostic marker. ~50% of BRAF V600E CRC are also MSI-H (sporadic CIMP-high tumors with MLH1 hypermethylation).

Detection

  • NGS (FoundationOne CDx, Tempus xT, Caris MI Profile) — standard, also flags MSI/MMR status.
  • IHC for MMR proteins (MLH1, MSH2, MSH6, PMS2) — co-tested.
  • Distinguish V600E from non-V600 BRAF mutations (class II/III) — biology is different.

FDA-approved targeted therapies

DrugIndicationLineTier
Encorafenib + cetuximabBRAF V600E mCRC, post-1L (BEACON CRC)2L+I-A
Encorafenib + cetuximab + chemotherapyBRAF V600E mCRC, 1L (BREAKWATER)1LI-A
PembrolizumabMSI-H / dMMR mCRC (including BRAF V600E + MSI-H subset)1L if MSI-HI-A

Tier = AMP/ASCO/CAP 2017 (Li MM et al., J Mol Diagn 2017). Drug names link to openFDA labels where available. Synthetic data; consult primary sources before treatment.

Resistance pathways

  • MAPK pathway reactivation: KRAS or NRAS mutations emerging at progression.
  • Receptor tyrosine kinase amplification (MET, EGFR).
  • PIK3CA mutations enabling bypass.

Pharmacogenomics

Encorafenib is a CYP3A4 substrate. Co-administration with strong CYP3A4 inhibitors or inducers requires monitoring and dose adjustment. Cetuximab carries a risk of severe infusion reactions in patients with high serum levels of pre-formed IgE against galactose-alpha-1,3-galactose (more common in the southeastern US).

Frequently asked questions

Why doesn't BRAF inhibitor monotherapy work in CRC the way it does in melanoma?
Colorectal tumors have high baseline EGFR expression. BRAF inhibition triggers feedback EGFR reactivation that re-stimulates the MAPK pathway, neutralizing the BRAF blockade. Melanoma cells have lower EGFR expression, so monotherapy works. The cetuximab (or panitumumab) addition is what restores BRAF dependence in CRC.
What if the patient is BRAF V600E AND MSI-H?
Strong consideration for first-line pembrolizumab. KEYNOTE-177 showed pembrolizumab superior to chemotherapy for MSI-H mCRC including the BRAF V600E subset. If immunotherapy fails or is contraindicated, encorafenib + cetuximab is the next move.
Does class II or class III BRAF mutation respond to encorafenib + cetuximab?
No. The BEACON regimen is specific to BRAF V600E (class I). Class II (dimer-dependent, RAS-independent) and class III (kinase-impaired, RAS-dependent) BRAF alterations have different biology and different (largely investigational) targeting strategies.

Citations